AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
AAPL   320.40 (+0.77%)
MSFT   182.05 (-0.65%)
FB   228.18 (+1.37%)
GOOGL   1,431.92 (-0.11%)
AMZN   2,464.00 (+0.89%)
NVDA   349.67 (-1.51%)
CGC   16.10 (-7.31%)
BABA   204.76 (-1.27%)
MU   46.82 (-2.28%)
GE   6.74 (+2.59%)
TSLA   881.58 (+5.58%)
F   5.84 (+2.10%)
DIS   119.19 (+1.61%)
NFLX   420.29 (+0.13%)
BAC   24.74 (+2.57%)
BA   151.91 (+4.15%)
Log in

NASDAQ:GERNGeron Stock Price, Forecast & News

$1.73
+0.12 (+7.45 %)
(As of 06/1/2020 11:18 AM ET)
Add
Compare
Today's Range
$1.62
Now: $1.73
$1.78
50-Day Range
$1.08
MA: $1.37
$2.06
52-Week Range
$0.75
Now: $1.73
$2.40
Volume102,994 shs
Average Volume4.43 million shs
Market Capitalization$351.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Read More
Geron logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.68 per share

Profitability

Net Income$-68,550,000.00
Net Margins-16,449.23%

Miscellaneous

Employees45
Market Cap$351.74 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Geron (NASDAQ:GERN) Frequently Asked Questions

How has Geron's stock been impacted by COVID-19 (Coronavirus)?

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GERN shares have increased by 67.0% and is now trading at $1.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Geron?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Thursday, May, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.04. The biopharmaceutical company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.11 million. Geron had a negative return on equity of 52.95% and a negative net margin of 16,449.23%. During the same period last year, the company posted ($0.05) EPS. View Geron's earnings history.

What price target have analysts set for GERN?

5 brokerages have issued twelve-month price targets for Geron's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Geron's share price to reach $3.60 in the next twelve months. This suggests a possible upside of 109.3% from the stock's current price. View analysts' price targets for Geron.

Has Geron been receiving favorable news coverage?

Media headlines about GERN stock have been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Geron earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutGeron.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 69, Pay $1.15M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 51, Pay $687.17k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 56, Pay $705.69k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 56, Pay $673.36k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 45, Pay $968.2k)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.82%), State Street Corp (1.86%), Geode Capital Management LLC (1.37%), Two Sigma Investments LP (0.80%), Bank of New York Mellon Corp (0.42%) and Two Sigma Advisers LP (0.33%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View institutional ownership trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, SG Americas Securities LLC, Virtus ETF Advisers LLC, Creative Planning, and Deutsche Bank AG. View insider buying and selling activity for Geron.

Which major investors are buying Geron stock?

GERN stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Geode Capital Management LLC, Invesco Ltd., State Street Corp, BlackRock Inc., Advisor Group Holdings Inc., and Commonwealth Equity Services LLC. View insider buying and selling activity for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.72.

How big of a company is Geron?

Geron has a market capitalization of $349.71 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.